Julie McHugh Joins HealthCare Royalty Partners Strategic Advisory Board
STAMFORD, Conn. -- May 10, 2017 -- HealthCare Royalty Partners ("HCR"), a global healthcare investment firm, today announced the appointment of life sciences industry veteran Julie McHugh to the firm's Strategic Advisory Board.
"Julie has vast experience as a pharmaceutical executive, spanning from large multinational pharmaceutical companies to smaller venture backed companies. Julie's insights and expertise in the development and commercialization of pharmaceutical products will be invaluable in assisting our team's evaluation of potential investments," said Clarke B. Futch, Managing Partner at HCR.
Ms. McHugh spent over a decade at Johnson & Johnson ("J&J") in various positions, including as Company Group Chairman, Global Virology Business Unit and as President of the Centocor division of J&J. More recently, Ms. McHugh served as the Chief Operating Officer of Endo Health Solutions and as President and Chief Executive Officer of Nora Therapeutics. Prior to Centocor, Ms. McHugh worked at Astra Merck and Rhone-Poulenc Rorer Pharmaceuticals, after beginning her career at Smithkline. Ms. McHugh received a Bachelor of Science degree in Finance from The Pennsylvania State University and a Master of Business Administration in International Management from Saint Joseph's University. She currently serves as a member of the Board of Directors of New Xellia Group A/S, Ironwood Pharmaceuticals, Inc., Trevena, Inc., Aerie Pharmaceuticals, Inc. and Lantheus Medical Imaging, Inc. Ms. McHugh is also a member of The Penn State Smeal College of Business Board of Visitors.
"I have been thoroughly impressed with the intellect and diligence capabilities of the team at HCR. I look forward to working with HCR as they seek to provide bespoke, non-dilutive financing to innovative companies that provide medically necessary products to patients around the world," commented Ms. McHugh.
About HealthCare Royalty Partners
HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets. HCR has $3.5 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, and Boston. Since 2003, HCR's senior professionals have completed more than 60 healthcare investments. For more information, visit www.healthcareroyalty.com.
# # #